DDInter704 DDInter462
Everolimus is a derivative of Rapamycin (sirolimus), and works similarly to Rapamycin as an mTOR (mammalian target of rapamycin) inhibitor. It is currently used as an immunosuppressant to prevent rejection of organ transplants. In a similar fashion to other mTOR inhibitors Everolimus' effect is solely on the mTORC1 protein and not on the mTORC2 protein.
Dabrafenib mesylate (Tafinlar) is a reversible ATP-competitive kinase inhibitor and targets the MAPK pathway. It was approved on May 29, 2013, for the treatment of melanoma with V600E or V6000K mutation. It was also used for metastatic non-small cell lung cancer with the same mutation. In May 2018, Tafinlar (dabrafenib), in combination with Mekinist (), was approved to treat anaplastic thyroid cancer caused by an abnormal BRAF V600E gene.
Everolimus {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Dabrafenib
Everolimus {u} (Compound) upregulates {v} (Gene) CDKN1A
CDKN1A {u} (Gene) is upregulated by {v} (Compound) Dabrafenib
Everolimus {u} (Compound) downregulates {v} (Gene) NIPSNAP1
NIPSNAP1 {u} (Gene) is upregulated by {v} (Compound) Dabrafenib
Everolimus {u} (Compound) downregulates {v} (Gene) KIF14
KIF14 {u} (Gene) is downregulated by {v} (Compound) Dabrafenib
Everolimus {u} (Compound) upregulates {v} (Gene) BAG3
BAG3 {u} (Gene) is downregulated by {v} (Compound) Dabrafenib
Everolimus {u} (Compound) causes {v} (Side Effect) Abdominal pain
Abdominal pain {u} (Side Effect) is caused by {v} (Compound) Dabrafenib
Everolimus {u} (Compound) resembles {v} (Compound) Sirolimus
Sirolimus {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dabrafenib
Everolimus {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Bortezomib
Bortezomib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Dabrafenib
Everolimus {u} (Compound) upregulates {v} (Gene) CDKN1A
CDKN1A {u} (Gene) is regulated by {v} (Gene) SIK1
SIK1 {u} (Gene) is bound by {v} (Compound) Dabrafenib
Everolimus {u} (Compound) downregulates {v} (Gene) NIPSNAP1
NIPSNAP1 {u} (Gene) is regulated by {v} (Gene) CDKN1A
CDKN1A {u} (Gene) is upregulated by {v} (Compound) Dabrafenib
Everolimus (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Dabrafenib (Compound)
Everolimus (Compound) upregulates CDKN1A (Gene) and CDKN1A (Gene) is upregulated by Dabrafenib (Compound)
Everolimus (Compound) downregulates NIPSNAP1 (Gene) and NIPSNAP1 (Gene) is upregulated by Dabrafenib (Compound)
Everolimus (Compound) downregulates KIF14 (Gene) and KIF14 (Gene) is downregulated by Dabrafenib (Compound)
Everolimus (Compound) upregulates BAG3 (Gene) and BAG3 (Gene) is downregulated by Dabrafenib (Compound)
Everolimus (Compound) causes Abdominal pain (Side Effect) and Abdominal pain (Side Effect) is caused by Dabrafenib (Compound)
Everolimus (Compound) resembles Sirolimus (Compound) and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Dabrafenib
Everolimus (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Bortezomib (Compound) and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Dabrafenib
Everolimus (Compound) upregulates CDKN1A (Gene) and CDKN1A (Gene) is regulated by SIK1 (Gene) and SIK1 (Gene) is bound by Dabrafenib (Compound)
Everolimus (Compound) downregulates NIPSNAP1 (Gene) and NIPSNAP1 (Gene) is regulated by CDKN1A (Gene) and CDKN1A (Gene) is upregulated by Dabrafenib (Compound)